Candriam SCA’s Cabaletta Bio CABA Stock Holding History

Candriam SCA’s Portfolio CABA Stock Details CABA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-200,000	Closed	-$3.41M	–	694
2024 Q1	$3.41M	Buy	+200,000	New	+$4.29M	0.02%	415

Other funds holding CABA

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Candriam SCA's CABA Position: Q2 2024 in Review

Candriam SCA sold out of Cabaletta Bio (CABA) in Q2 2024, closing a stake of 200,000 shares — an estimated $3.41M sold.

Candriam SCA first reported a position in CABA in Q1 2024 and held it in 1 quarter. The position peaked at $3.41M in Q1 2024. 142 funds tracked by Wall St. Rank hold CABA as of Q2 2024.

Candriam SCA reported no remaining Cabaletta Bio position as of Q2 2024 after selling out during the quarter.
Candriam SCA sold 200,000 Cabaletta Bio shares in Q2 2024, an estimated $3.41M.
Candriam SCA first reported a position in Cabaletta Bio in Q1 2024 and held it in 1 quarter.
Candriam SCA's Cabaletta Bio position peaked at $3.41M in Q1 2024.
142 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2024.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.